+65 3158 9910
1300 798 820
+64 9801 0299
Singapore’s Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatment of patients with 4th line GIST QINLOCK significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in the INVICTUS Phase 3 Study1,2 Singapore, 8 May 2023: Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is
Singapore, 12 July 2022: A novel therapy to treat rare gastrointestinal stromal tumours (GIST) has been accepted for evaluation by Singapore’s Health Sciences Authority.
QINLOCK® (ripretinib) now PBS listed for Australian patients QINLOCK is the first new reimbursed therapy to treat advanced GIST in more than a decade Leading Australian oncologist says the listing will help to “buy patients more time” Data shows QINLOCK reduces risk of disease progression by 85%1, 2 14 November, 2021: AUSTRALIAN cancer patients